Literature DB >> 19760630

Opioid use affects antioxidant activity and purine metabolism: preliminary results.

Paolo Mannelli1, Ashwin Patkar, Steve Rozen, Wayne Matson, Ranga Krishnan, Rima Kaddurah-Daouk.   

Abstract

OBJECTIVE: More must be learned about metabolic and biochemical alterations that contribute to the development and expression of drug dependence. Experimental opioid administration influences mechanisms and indices of oxidative stress, such as antioxidant compounds and purine metabolism. We examined perturbations of neurotransmitter-related pathways in opioid dependence (OD).
METHODS: In this preliminary study, we used a targeted metabolomics platform to explore whether biochemical changes were associated with OD by comparing OD individuals (n = 14) and non-drug users (n = 10).
RESULTS: OD patients undergoing short-term methadone detoxification showed altered oxidation-reduction activity, as confirmed by higher plasma levels of alpha- and gamma-tocopherol and increased GSH/GSSG ratio. OD individuals had also altered purine metabolism, showing increased concentration of guanine and xanthosine, with decreased guanosine, hypoxanthine and hypoxanthine/xanthine and xanthine/xanthosine ratios. Other drug use in addition to opioids was associated with partly different biochemical changes.
CONCLUSIONS: This is a preliminary investigation using metabolomics and showing multiple peripheral alterations of metabolic pathways in OD. Further studies should explore the metabolic profile of conditions of opioid abuse, withdrawal and long-term abstinence in relation to agonist and antagonist treatment and investigate biochemical signatures of opioid substances and medications. Copyright (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19760630      PMCID: PMC3183957          DOI: 10.1002/hup.1068

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  69 in total

Review 1.  Metabolomics in the study of aging and caloric restriction.

Authors:  Bruce S Kristal; Yevgeniya I Shurubor; Rima Kaddurah-Daouk; Wayne R Matson
Journal:  Methods Mol Biol       Date:  2007

2.  Metabolomic analysis and signatures in motor neuron disease.

Authors:  Steve Rozen; Merit E Cudkowicz; Mikhail Bogdanov; Wayne R Matson; Bruce S Kristal; Chris Beecher; Scott Harrison; Paul Vouros; Jimmy Flarakos; Karen Vigneau-Callahan; Theodore D Matson; Kristyn M Newhall; M Flint Beal; Robert H Brown; Rima Kaddurah-Daouk
Journal:  Metabolomics       Date:  2005       Impact factor: 4.290

3.  Acute decreases in cerebrospinal fluid glutathione levels after intracerebroventricular morphine for cancer pain.

Authors:  L C Goudas; A Langlade; A Serrie; W Matson; P Milbury; C Thurel; P Sandouk; D B Carr
Journal:  Anesth Analg       Date:  1999-11       Impact factor: 5.108

Review 4.  Trophic effects of purines in neurons and glial cells.

Authors:  M P Rathbone; P J Middlemiss; J W Gysbers; C Andrew; M A Herman; J K Reed; R Ciccarelli; P Di Iorio; F Caciagli
Journal:  Prog Neurobiol       Date:  1999-12       Impact factor: 11.685

5.  Evidence for the involvement of cytosolic 5'-nucleotidase (cN-II) in the synthesis of guanine nucleotides from xanthosine.

Authors:  Catia Barsotti; Rossana Pesi; Michela Giannecchini; Piero L Ipata
Journal:  J Biol Chem       Date:  2005-02-06       Impact factor: 5.157

6.  Comparative study of activities in reactive oxygen species production/defense system in mitochondria of rat brain and liver, and their susceptibility to methylmercury toxicity.

Authors:  N Mori; A Yasutake; K Hirayama
Journal:  Arch Toxicol       Date:  2007-04-27       Impact factor: 5.153

7.  Morphine enhances purine nucleotide catabolism in vivo and in vitro.

Authors:  Chang Liu; Jian-kai Liu; Mu-jie Kan; Lin Gao; Hai-ying Fu; Hang Zhou; Min Hong
Journal:  Acta Pharmacol Sin       Date:  2007-08       Impact factor: 6.150

8.  Global ischemia induces NMDA receptor-mediated c-fos expression in neurons resistant to injury in gerbil hippocampus.

Authors:  Y Uemura; N W Kowall; M F Beal
Journal:  Brain Res       Date:  1991-03-01       Impact factor: 3.252

9.  Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial.

Authors:  Paolo Mannelli; Ashwin A Patkar; Kathi Peindl; David A Gorelick; Li-Tzy Wu; Edward Gottheil
Journal:  Addict Biol       Date:  2008-08-19       Impact factor: 4.280

10.  [Effect of chronic morphine treatment on free radical state].

Authors:  D A Miskevich; N E Petushok; V V Lelevich; S V Lelevich; A N Borodinskiĭ
Journal:  Biomed Khim       Date:  2007 Mar-Apr
View more
  15 in total

1.  3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia.

Authors:  Ruth Condray; George G Dougherty; Matcheri S Keshavan; Ravinder D Reddy; Gretchen L Haas; Debra M Montrose; Wayne R Matson; Joseph McEvoy; Rima Kaddurah-Daouk; Jeffrey K Yao
Journal:  Int J Neuropsychopharmacol       Date:  2011-01-28       Impact factor: 5.176

2.  Metabolomic changes in autopsy-confirmed Alzheimer's disease.

Authors:  Rima Kaddurah-Daouk; Steve Rozen; Wayne Matson; Xianlin Han; Christine M Hulette; James R Burke; P Murali Doraiswamy; Kathleen A Welsh-Bohmer
Journal:  Alzheimers Dement       Date:  2010-11-13       Impact factor: 21.566

3.  Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia.

Authors:  Jeffrey K Yao; George G Dougherty; Ravinder D Reddy; Matcheri S Keshavan; Debra M Montrose; Wayne R Matson; Joseph McEvoy; Rima Kaddurah-Daouk
Journal:  PLoS One       Date:  2010-03-03       Impact factor: 3.240

Review 4.  Vitamin C, Pain and Opioid Use Disorder.

Authors:  Erica Zelfand
Journal:  Integr Med (Encinitas)       Date:  2020-06

5.  Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.

Authors:  Y Ji; S Hebbring; H Zhu; G D Jenkins; J Biernacka; K Snyder; M Drews; O Fiehn; Z Zeng; D Schaid; D A Mrazek; R Kaddurah-Daouk; R M Weinshilboum
Journal:  Clin Pharmacol Ther       Date:  2010-11-24       Impact factor: 6.875

6.  Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics.

Authors:  Xianlin Han; Steve Rozen; Stephen H Boyle; Caroline Hellegers; Hua Cheng; James R Burke; Kathleen A Welsh-Bohmer; P Murali Doraiswamy; Rima Kaddurah-Daouk
Journal:  PLoS One       Date:  2011-07-11       Impact factor: 3.240

7.  Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept.

Authors:  R Kaddurah-Daouk; S H Boyle; W Matson; S Sharma; S Matson; H Zhu; M B Bogdanov; E Churchill; R R Krishnan; A J Rush; E Pickering; M Delnomdedieu
Journal:  Transl Psychiatry       Date:  2011       Impact factor: 6.222

Review 8.  Redox-based epigenetic status in drug addiction: a potential contributor to gene priming and a mechanistic rationale for metabolic intervention.

Authors:  Malav S Trivedi; Richard Deth
Journal:  Front Neurosci       Date:  2015-01-22       Impact factor: 4.677

9.  Cellular Metabolomics Profiles Associated With Drug Chemosensitivity in AML.

Authors:  Bradley Stockard; Neha Bhise; Miyoung Shin; Joy Guingab-Cagmat; Timothy J Garrett; Stanley Pounds; Jatinder K Lamba
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

10.  Associations between purine metabolites and monoamine neurotransmitters in first-episode psychosis.

Authors:  Jeffrey K Yao; George G Dougherty; Ravinder D Reddy; Wayne R Matson; Rima Kaddurah-Daouk; Matcheri S Keshavan
Journal:  Front Cell Neurosci       Date:  2013-06-11       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.